Update on the MESSINA Phase III trial for Fasenra in eosinophilic esophagitis
MESSINA did not meet one of the two dual-primary endpoints, demonstrating a statistically significant improvement in histological disease remission with Fasenra, but not in dysphagia symptoms, compared to placebo.Eosinophilic esophagitis (EoE) is a rare, progressive, chronic inflammatory disease of the esophagus currently believed to be characterised by the abnormal presence of eosinophils, a type of white blood cell, in the inner lining of the esophagus.[1-3 ]Patients experience difficulty with swallowing (dysphagia), pain, food getting stuck and anxiety.[4,5] High-level results from
